Tickers — I

61 tickers
Ranks this page's recent reports by score.
Imperial Oil Limited
IMO·Energy
B ★★★Hold
Current$138.10
Target$126.36
Return-8.5%
Nov 1, 2026

Imperial Oil's integrated assets, resilient balance sheet, and aggressive capital returns support long-term shareholder value, but elevated historical valuation multiples and cyclical refining profits limit near-term upside.

Score
68
Intercontinental Exchange, Inc.
ICE·Financials
S ★★★★★Strong Buy
Current$168.85
Target$193.20
Return+14.4%
Nov 1, 2026

ICE combines entrenched exchange network effects, recurring financial data revenue, and strong cash generation at an attractive valuation, although MarketAxess acquisition financing and integration introduce meaningful execution risk.

Score
86
ING Groep N.V.
ING·Financials
B ★★★Hold
Current$31.46
Target$34.10
Return+8.4%
Nov 1, 2026

ING combines a durable European deposit franchise, strong tangible-equity returns and substantial shareholder distributions, but its historical valuation premium and sensitivity to interest rates and credit losses limit the margin of safety.

Score
74
Ionis Pharmaceuticals, Inc.
IONS·Healthcare
D ★Strong Sell
Current$43.52
Nov 1, 2026

Ionis has a differentiated RNA therapeutics platform and expanding approved-drug portfolio, but persistent cash burn, clinical setbacks, and demanding commercialization assumptions constrain its risk-adjusted investment appeal.

Score
46
Independence Realty Trust, Inc.
IRT·Real Estate
B ★★★Hold
Current$14.72
Target$17.22
Return+17.0%
Oct 31, 2026

IRT combines recurring apartment rental cash flow, an attractive dividend, and potential Centerspace merger synergies, but elevated leverage, apartment supply pressure, and integration uncertainty limit conviction.

Score
71
Indivior Pharmaceuticals, Inc.
INDV·Healthcare
B ★★★Hold
Current$35.37
Target$39.60
Return+12.0%
Oct 31, 2026

Indivior combines a profitable, growing addiction-treatment franchise with potential Supernus merger synergies, but weak cash conversion, new financing obligations, and integration uncertainty constrain its investment appeal.

Score
67
IDEX Corporation
IEX·Industrials
A ★★★★Buy
Current$233.84
Target$252.50
Return+8.0%
Oct 31, 2026

IDEX combines high-margin niche industrial franchises, strong cash conversion, and improving organic demand to compound earnings, although premium valuation and acquisition execution risks limit its margin of safety.

Score
75
International Paper Company
IP·Consumer Discretionary
B ★★★Hold
Current$36.37
Target$40.00
Return+10.0%
Oct 31, 2026

International Paper offers a cyclical earnings recovery opportunity through North American margin improvement and an EMEA separation, but weak free cash flow, substantial debt, and restructuring uncertainty constrain the upside case.

Score
67
Invitation Homes Inc.
INVH·Real Estate
A ★★★★Buy
Current$26.56
Target$29.24
Return+10.1%
Oct 31, 2026

Invitation Homes offers recurring single-family rental income, an attractive dividend, and potential valuation recovery through disciplined capital recycling, although slowing rent growth and property cost inflation threaten AFFO expansion.

Score
78
ICON Public Limited Company
ICLR·Healthcare
C ★★Sell
Current$209.37
Oct 30, 2026

ICON's global CRO franchise, $24.5B backlog, and strong cash generation provide recovery potential, but unresolved accounting-control weaknesses and weak organic growth outweigh its relative valuation discount.

Score
59
InvenTrust Properties Corp.
IVT·Real Estate
B ★★★Hold
Current$31.03
Target$33.28
Return+7.3%
Oct 30, 2026

InvenTrust offers defensive grocery-anchored Sun Belt rental income and improving FFO, but its historical valuation premium, acquisition dependence, and regional concentration limit the margin of safety.

Score
72